Showing results (401-410 of 408) with videos related to
Sort By:
Pageof 41
You have reached the last page of results.This site can display upto 408 results.
The International Journal on Drug Policy|June 24, 2025
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use: the SHARP-C studyJoshua Ang, Behzad Hajarizadeh, Shane Tillakeratne, et al.Environmental Science & Technology|February 10, 2022
In Situ Enhancement and Isotopic Labeling of Biogenic Coalbed MethaneElliott P Barnhart, Leslie F Ruppert, Randy Hiebert, et al.The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.Cell Reports|December 3, 2014
Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomesChristina L Zheng, Nicholas J Wang, Jongsuk Chung, et al.Journal of Science and Medicine in Sport|October 12, 2007
The lifestyle of our kids (LOOK) project: outline of methodsRichard D Telford, Shona L Bass, Marc M Budge, et al.The Lancet. Gastroenterology & Hepatology|October 8, 2017
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in EuropeAlison D Marshall, Evan B Cunningham, Stine Nielsen, et al.Pageof 41